Top

Published in:

Open Access 01-11-2018 | Meeting Report

The 10th Biennial Hatter Cardiovascular Institute workshop: cellular protection—evaluating new directions in the setting of myocardial infarction, ischaemic stroke, and cardio-oncology

Authors: Sean M. Davidson, Sapna Arjun, Maryna V. Basalay, Robert M. Bell, Daniel I. Bromage, Hans Erik Bøtker, Richard D. Carr, John Cunningham, Arjun K. Ghosh, Gerd Heusch, Borja Ibanez, Petra Kleinbongard, Sandrine Lecour, Helen Maddock, Michel Ovize, Malcolm Walker, Marlene Wiart, Derek M. Yellon

Published in: Basic Research in Cardiology | Issue 6/2018

Abstract

Due to its poor capacity for regeneration, the heart is particularly sensitive to the loss of contractile cardiomyocytes. The onslaught of damage caused by ischaemia and reperfusion, occurring during an acute myocardial infarction and the subsequent reperfusion therapy, can wipe out upwards of a billion cardiomyocytes. A similar program of cell death can cause the irreversible loss of neurons in ischaemic stroke. Similar pathways of lethal cell injury can contribute to other pathologies such as left ventricular dysfunction and heart failure caused by cancer therapy. Consequently, strategies designed to protect the heart from lethal cell injury have the potential to be applicable across all three pathologies. The investigators meeting at the 10th Hatter Cardiovascular Institute workshop examined the parallels between ST-segment elevation myocardial infarction (STEMI), ischaemic stroke, and other pathologies that cause the loss of cardiomyocytes including cancer therapeutic cardiotoxicity. They examined the prospects for protection by remote ischaemic conditioning (RIC) in each scenario, and evaluated impasses and novel opportunities for cellular protection, with the future landscape for RIC in the clinical setting to be determined by the outcome of the large ERIC-PPCI/CONDI2 study. It was agreed that the way forward must include measures to improve experimental methodologies, such that they better reflect the clinical scenario and to judiciously select combinations of therapies targeting specific pathways of cellular death and injury.

http://www.dcn.ed.ac.uk/multipart/default.htm

https://www.astrazeneca.com/content/astraz/media-centre/press-releases/2018/farxiga-achieved-a-positive-result-in-the-phase-iii-declare-timi-58-trial-a-large-cardiovascular-outcomes-trial-in-17000-patients-with-type-2-diabetes-24092018.html

Ames A 3rd, Wright RL, Kowada M, Thurston JM, Majno G (1968) Cerebral ischemia. II. The no-reflow phenomenon. Am J Pathol 52:437–453PubMedPubMedCentral

Aronowski J, Strong R, Grotta JC (1997) Reperfusion injury: demonstration of brain damage produced by reperfusion after transient focal ischemia in rats. J Cereb Blood Flow Metab 17:1048–1056. https://doi.org/10.1097/00004647-199710000-00006 CrossRefPubMed

Astrup J (1982) Energy-requiring cell functions in the ischemic brain. Their critical supply and possible inhibition in protective therapy. J Neurosurg 56:482–497. https://doi.org/10.3171/jns.1982.56.4.0482 CrossRefPubMed

Audia JP, Yang X-M, Crockett ES, Housley N, Ul Haq E, O’Donnell K, Cohen MV, Downey JM, Alvarez DF (2018) Caspase-1 inhibition by VX-765 administered at reperfusion in P2Y12 receptor antagonist-treated rats provides long-term reduction in myocardial infarct size and preservation of ventricular function. Basic Res Cardiol 113:32. https://doi.org/10.1007/s00395-018-0692-z CrossRefPubMedPubMedCentral

Bai J, Lyden PD (2015) Revisiting cerebral postischemic reperfusion injury: new insights in understanding reperfusion failure, hemorrhage, and edema. Int J Stroke 10:143–152. https://doi.org/10.1111/ijs.12434 CrossRefPubMed

Baines CP, Kaiser RA, Purcell NH, Blair NS, Osinska H, Hambleton MA, Brunskill EW, Sayen MR, Gottlieb RA, Dorn GW, Robbins J, Molkentin JD (2005) Loss of cyclophilin D reveals a critical role for mitochondrial permeability transition in cell death. Nature 434:658–662. https://doi.org/10.1038/nature03434 CrossRefPubMed

Balami JS, Chen RL, Grunwald IQ, Buchan AM (2011) Neurological complications of acute ischaemic stroke. Lancet Neurol. 10:357–371. https://doi.org/10.1016/S1474-4422(10)70313-6 CrossRefPubMed

10.

Baxter GF, Hale SL, Miki T, Kloner RA, Cohen MV, Downey JM, Yellon DM (2000) Adenosine A1 agonist at reperfusion trial (AART): results of a three-center, blinded, randomized, controlled experimental infarct study. Cardiovasc Drugs Ther 14:607–614CrossRefPubMed

11.

Bell R, Beeuwkes R, Bøtker HE, Davidson S, Downey J, Garcia-Dorado D, Hausenloy DJ, Heusch G, Ibanez B, Kitakaze M, Lecour S, Mentzer R, Miura T, Opie L, Ovize M, Ruiz-Meana M, Schulz R, Shannon R, Walker M, Vinten-Johansen J, Yellon D (2012) Trials, tribulations and speculation! Report from the 7th Biennial Hatter Cardiovascular Institute Workshop. Basic Res Cardiol 107:300. https://doi.org/10.1007/s00395-012-0300-6 CrossRefPubMed

12.

Bell RM, Botker HE, Carr RD, Davidson SM, Downey JM, Dutka DP, Heusch G, Ibanez B, Macallister R, Stoppe C, Ovize M, Redington A, Walker JM, Yellon DM (2016) 9th Hatter Biannual Meeting: position document on ischaemia/reperfusion injury, conditioning and the ten commandments of cardioprotection. Basic Res Cardiol 111:41. https://doi.org/10.1007/s00395-016-0558-1 CrossRefPubMedPubMedCentral

13.

Bell RM, Yellon DM (2018) SGLT2 inhibitors: hypotheses on the mechanism of cardiovascular protection. Lancet Diabetes Endocrinol 6:435–437. https://doi.org/10.1016/S2213-8587(17)30314-5 CrossRefPubMed

14.

Bonita R, Pradhan R (2013) Cardiovascular toxicities of cancer chemotherapy. Semin Oncol 40:156–167. https://doi.org/10.1053/j.seminoncol.2013.01.004 CrossRefPubMed

15.

Botker HE, Hausenloy D, Andreadou I, Antonucci S, Boengler K, Davidson SM, Deshwal S, Devaux Y, Di Lisa F, Di Sante M, Efentakis P, Femmino S, Garcia-Dorado D, Giricz Z, Ibanez B, Iliodromitis E, Kaludercic N, Kleinbongard P, Neuhauser M, Ovize M, Pagliaro P, Rahbek-Schmidt M, Ruiz-Meana M, Schluter KD, Schulz R, Skyschally A, Wilder C, Yellon DM, Ferdinandy P, Heusch G (2018) Practical guidelines for rigor and reproducibility in preclinical and clinical studies on cardioprotection. Basic Res Cardiol 113:39. https://doi.org/10.1007/s00395-018-0696-8 CrossRefPubMedPubMedCentral

16.

Bromage DI, Pickard JM, Rossello X, Ziff OJ, Burke N, Yellon DM, Davidson SM (2017) Remote ischaemic conditioning reduces infarct size in animal in vivo models of ischaemia-reperfusion injury: a systematic review and meta-analysis. Cardiovasc Res 113:288–297. https://doi.org/10.1093/cvr/cvw219 CrossRefPubMed

17.

Cabrera-Fuentes HA, Aragones J, Bernhagen J, Boening A, Boisvert WA, Botker HE, Bulluck H, Cook S, Di Lisa F, Engel FB, Engelmann B, Ferrazzi F, Ferdinandy P, Fong A, Fleming I, Gnaiger E, Hernandez-Resendiz S, Kalkhoran SB, Kim MH, Lecour S, Liehn EA, Marber MS, Mayr M, Miura T, Ong SB, Peter K, Sedding D, Singh MK, Suleiman MS, Schnittler HJ, Schulz R, Shim W, Tello D, Vogel CW, Walker M, Li QO, Yellon DM, Hausenloy DJ, Preissner KT (2016) From basic mechanisms to clinical applications in heart protection, new players in cardiovascular diseases and cardiac theranostics: meeting report from the third international symposium on “New frontiers in cardiovascular research”. Basic Res Cardiol 111:69. https://doi.org/10.1007/s00395-016-0586-x CrossRefPubMedPubMedCentral

18.

Carvalho A, Cunha A, Rodrigues M, Figueiredo S, Paredes L, Gregorio T, Morais H, Pinheiro J, Cruz VT, Roriz JM, Pinho J, Ferreira C, Torre E, Nunes J, Castro S, Ribeiro M, Veloso M, Barros P (2017) Mechanical thrombectomy in acute ischemic stroke: initial single-center experience and comparison with randomized controlled trials. J Stroke Cerebrovasc Dis 26:589–594. https://doi.org/10.1016/j.jstrokecerebrovasdis.2016.11.116 CrossRefPubMed

19.

Chauveau F, Cho TH, Riou A, Langlois JB, Berthezene Y, Nighoghossian N, Wiart M (2012) Does acute behavioral testing reflect successful ischemia in rats with transient middle cerebral artery occlusion? Int J Stroke 7:465–472. https://doi.org/10.1111/j.1747-4949.2011.00710.x CrossRefPubMed

20.

Chen F, Suzuki Y, Nagai N, Jin L, Yu J, Wang H, Marchal G, Ni Y (2007) Rodent stroke induced by photochemical occlusion of proximal middle cerebral artery: evolution monitored with MR imaging and histopathology. Eur J Radiol 63:68–75. https://doi.org/10.1016/j.ejrad.2007.01.005 CrossRefPubMed

21.

Chouchani ET, Pell VR, Gaude E, Aksentijević D, Sundier SY, Robb EL, Logan A, Nadtochiy SM, Ord EN, Smith AC, Eyassu F, Shirley R, Hu CH, Dare AJ, James AM, Rogatti S, Hartley RC, Eaton S, Costa AS, Brookes PS, Davidson SM, Duchen MR, Saeb-Parsy K, Shattock MJ, Robinson AJ, Work LM, Frezza C, Krieg T, Murphy MP (2014) Ischaemic accumulation of succinate controls reperfusion injury through mitochondrial ROS. Nature 515:431–435. https://doi.org/10.1038/nature13909 CrossRefPubMedPubMedCentral

22.

Chung R, Maulik A, Hamarneh A, Hochhauser D, Hausenloy DJ, Walker JM, Yellon DM (2016) Effect of remote ischaemic conditioning in oncology patients undergoing chemotherapy: rationale and design of the ERIC-ONC study–a single-center, blinded, randomized controlled trial. Clin Cardiol 39:72–82. https://doi.org/10.1002/clc.22507 CrossRefPubMedPubMedCentral

23.

Cohen MV, Downey JM (2017) The impact of irreproducibility and competing protection from P2Y12 antagonists on the discovery of cardioprotective interventions. Basic Res Cardiol 112:64. https://doi.org/10.1007/s00395-017-0653-y CrossRefPubMed

24.

Crone SA, Zhao YY, Fan L, Gu Y, Minamisawa S, Liu Y, Peterson KL, Chen J, Kahn R, Condorelli G, Ross J Jr, Chien KR, Lee KF (2002) ErbB2 is essential in the prevention of dilated cardiomyopathy. Nat Med 8:459–465. https://doi.org/10.1038/nm0502-459 CrossRefPubMed

25.

Davidson SM, Ferdinandy P, Andreadou I, Bøtker HE, Heusch G, Ibáñez B, Ovize M, Schulz R, Yellon DM, Hausenloy DJ, Garcia-Dorado D (2018) Multi-target strategies to reduce myocardial ischemia/reperfusion injury. J Am Coll, Cardiol (In press)

26.

Davidson SM, Takov K, Yellon DM (2017) Exosomes and cardiovascular protection. Cardiovasc Drugs Ther 31:77–86. https://doi.org/10.1007/s10557-016-6698-6 CrossRefPubMed

27.

Davidson SM, Yellon DM (2018) Exosomes and cardioprotection—a critical analysis. Mol Aspects Med 60:104–114. https://doi.org/10.1016/j.mam.2017.11.004 CrossRefPubMedPubMedCentral

28.

Davidson SM, Yellon DM, Murphy MP, Duchen (2012) Slow calcium waves and redox changes precede mitochondrial permeability transition pore opening in the intact heart during hypoxia and reoxygenation. Cardiovasc Res 93:445–453. https://doi.org/10.1093/cvr/cvr349 CrossRefPubMed

29.

Donnan GA, Davis SM (2002) Neuroimaging, the ischaemic penumbra, and selection of patients for acute stroke therapy. Lancet Neurol 1:417–425CrossRefPubMed

30.

Donnan GA, Fisher M, Macleod M, Davis SM (2008) Stroke. Lancet 371:1612–1623. https://doi.org/10.1016/S0140-6736(08)60694-7 CrossRefPubMed

31.

Eitel I, Desch S, de Waha S, Fuernau G, Gutberlet M, Schuler G, Thiele H (2011) Long-term prognostic value of myocardial salvage assessed by cardiovascular magnetic resonance in acute reperfused myocardial infarction. Heart 97:2038–2045. https://doi.org/10.1136/heartjnl-2011-300098 CrossRefPubMed

32.

Fadini GP, Cosentino F (2018) Diabetes and ischaemic stroke: a deadly association. Eur Heart J 39:2387–2389. https://doi.org/10.1093/eurheartj/ehy033 CrossRefPubMed

33.

Feigin VL, Forouzanfar MH, Krishnamurthi R, Mensah GA, Connor M, Bennett DA, Moran AE, Sacco RL, Anderson L, Truelsen T, O’Donnell M, Venketasubramanian N, Barker-Collo S, Lawes CM, Wang W, Shinohara Y, Witt E, Ezzati M, Naghavi M, Murray C, Global Burden of Diseases I, Risk Factors S, the GBDSEG (2014) Global and regional burden of stroke during 1990–2010: findings from the Global Burden of Disease Study 2010. Lancet 383:245–254CrossRefPubMedPubMedCentral

34.

Fisher M, Feuerstein G, Howells DW, Hurn PD, Kent TA, Savitz SI, Lo EH, Group S (2009) Update of the stroke therapy academic industry roundtable preclinical recommendations. Stroke 40:2244–2250. https://doi.org/10.1161/strokeaha.108.541128 CrossRefPubMedPubMedCentral

35.

Furie KL, Jayaraman MV (2018) 2018 Guidelines for the early management of patients with acute ischemic stroke. Stroke 49:509–510. https://doi.org/10.1161/STROKEAHA.118.020176 CrossRefPubMed

36.

Gaspar A, Lourenco AP, Pereira MA, Azevedo P, Roncon-Albuquerque R Jr, Marques J, Leite-Moreira AF (2018) Randomized controlled trial of remote ischaemic conditioning in ST-elevation myocardial infarction as adjuvant to primary angioplasty (RIC-STEMI). Basic Res Cardiol 113:14. https://doi.org/10.1007/s00395-018-0672-3 CrossRefPubMed

37.

Gharanei M, Hussain A, Janneh O, Maddock H (2013) Attenuation of doxorubicin-induced cardiotoxicity by mdivi-1: a mitochondrial division/mitophagy inhibitor. PLoS One 8:e77713. https://doi.org/10.1371/journal.pone.0077713 CrossRefPubMedPubMedCentral

38.

Gharanei M, Hussain A, Janneh O, Maddock HL (2013) Doxorubicin induced myocardial injury is exacerbated following ischaemic stress via opening of the mitochondrial permeability transition pore. Toxicol Appl Pharmacol 268:149–156. https://doi.org/10.1016/j.taap.2012.12.003 CrossRefPubMed

39.

Ginsberg MD (2016) Expanding the concept of neuroprotection for acute ischemic stroke: the pivotal roles of reperfusion and the collateral circulation. Prog Neurobiol 145–146:46–77. https://doi.org/10.1016/j.pneurobio.2016.09.002 CrossRefPubMed

40.

Hausenloy DJ, Barrabes JA, Botker HE, Davidson SM, Di Lisa F, Downey J, Engstrom T, Ferdinandy P, Carbrera-Fuentes HA, Heusch G, Ibanez B, Iliodromitis EK, Inserte J, Jennings R, Kalia N, Kharbanda R, Lecour S, Marber M, Miura T, Ovize M, Perez-Pinzon MA, Piper HM, Przyklenk K, Schmidt MR, Redington A, Ruiz-Meana M, Vilahur G, Vinten-Johansen J, Yellon DM, Garcia-Dorado D (2016) Ischaemic conditioning and targeting reperfusion injury: a 30 year voyage of discovery. Basic Res Cardiol 111:70. https://doi.org/10.1007/s00395-016-0588-8 CrossRefPubMedPubMedCentral

41.

Hausenloy DJ, Botker HE, Engstrom T, Erlinge D, Heusch G, Ibanez B, Kloner RA, Ovize M, Yellon DM, Garcia-Dorado D (2017) Targeting reperfusion injury in patients with ST-segment elevation myocardial infarction: trials and tribulations. Eur Heart J 38:935–941. https://doi.org/10.1093/eurheartj/ehw145 CrossRefPubMed

42.

Hausenloy DJ, Candilio L, Evans R, Ariti C, Jenkins DP, Kolvekar S, Knight R, Kunst G, Laing C, Nicholas J, Pepper J, Robertson S, Xenou M, Clayton T, Yellon DM, Investigators ET (2015) Remote ischemic preconditioning and outcomes of cardiac surgery. N Engl J Med 373:1408–1417. https://doi.org/10.1056/NEJMoa1413534 CrossRefPubMed

43.

Hausenloy DJ, Garcia-Dorado D, Botker HE, Davidson SM, Downey J, Engel FB, Jennings R, Lecour S, Leor J, Madonna R, Ovize M, Perrino C, Prunier F, Schulz R, Sluijter JPG, Van Laake LW, Vinten-Johansen J, Yellon DM, Ytrehus K, Heusch G, Ferdinandy P (2017) Novel targets and future strategies for acute cardioprotection: position Paper of the European Society of Cardiology Working Group on Cellular Biology of the Heart. Cardiovasc Res 113:564–585. https://doi.org/10.1093/cvr/cvx049 CrossRefPubMed

44.

Hausenloy DJ, Kharbanda R, Rahbek Schmidt M, Moller UK, Ravkilde J, Okkels Jensen L, Engstrom T, Garcia Ruiz JM, Radovanovic N, Christensen EF, Sorensen HT, Ramlall M, Bulluck H, Evans R, Nicholas J, Knight R, Clayton T, Yellon DM, Botker HE (2015) Effect of remote ischaemic conditioning on clinical outcomes in patients presenting with an ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention. Eur Heart J 36:1846–1848. https://doi.org/10.1093/eurheartj/ehv249 CrossRefPubMed

45.

Hazell AS (2007) Excitotoxic mechanisms in stroke: an update of concepts and treatment strategies. Neurochem Int 50:941–953. https://doi.org/10.1016/j.neuint.2007.04.026 CrossRefPubMed

46.

Heusch G (2018) 25 years of remote ischemic conditioning: from laboratory curiosity to clinical outcome. Basic Res Cardiol 113:15. https://doi.org/10.1007/s00395-018-0673-2 CrossRefPubMed

47.

Heusch G (2018) Cardioprotection research must leave its comfort zone. Eur Heart J 39:3393–3395. https://doi.org/10.1093/eurheartj/ehy253 CrossRefPubMed

48.

Heusch G (2016) The coronary circulation as a target of cardioprotection. Circ Res 118:1643–1658. https://doi.org/10.1161/CIRCRESAHA.116.308640 CrossRefPubMed

49.

Heusch G (2017) Critical issues for the translation of cardioprotection. Circ Res 120:1477–1486. https://doi.org/10.1161/CIRCRESAHA.117.310820 CrossRefPubMed

50.

Heusch G, Botker HE, Przyklenk K, Redington A, Yellon D (2015) Remote ischemic conditioning. J Am Coll Cardiol 65:177–195. https://doi.org/10.1016/j.jacc.2014.10.031 CrossRefPubMedPubMedCentral

51.

Heusch G, Gersh BJ (2017) The pathophysiology of acute myocardial infarction and strategies of protection beyond reperfusion: a continual challenge. Eur Heart J 38:774–784. https://doi.org/10.1093/eurheartj/ehw224 CrossRefPubMed

52.

Heusch G, Kleinbongard P, Skyschally A (2013) Myocardial infarction and coronary microvascular obstruction: an intimate, but complicated relationship. Basic Res Cardiol 108:380. https://doi.org/10.1007/s00395-013-0380-y CrossRefPubMed

53.

Heusch G, Libby P, Gersh B, Yellon D, Bohm M, Lopaschuk G, Opie L (2014) Cardiovascular remodelling in coronary artery disease and heart failure. Lancet 383:1933–1943. https://doi.org/10.1016/S0140-6736(14)60107-0 CrossRefPubMedPubMedCentral

54.

Heusch G, Rassaf T (2016) Time to give up on cardioprotection? A critical appraisal of clinical studies on ischemic pre-, post-, and remote conditioning. Circ Res 119:676–695. https://doi.org/10.1161/CIRCRESAHA.116.308736 CrossRefPubMed

55.

Heusch G, Skyschally A, Kleinbongard P (2018) Translation, translation, translation. The need for large animal studies in cardioprotection research. Circ Res 123:931–933. https://doi.org/10.1161/CIRCRESAHA.118.313947 CrossRefPubMed

56.

Heusch G, Skyschally A, Schulz R (2011) The in situ pig heart with regional ischemia/reperfusion—ready for translation. J Mol Cell Cardiol 50:951–963. https://doi.org/10.1016/j.yjmcc.2011.02.016 CrossRefPubMed

57.

Ibanez B, Heusch G, Ovize M, Van de Werf F (2015) Evolving therapies for myocardial ischemia/reperfusion injury. J Am Coll Cardiol 65:1454–1471. https://doi.org/10.1016/j.jacc.2015.02.032 CrossRefPubMed

58.

Ibanez B, James S, Agewall S, Antunes MJ, Bucciarelli-Ducci C, Bueno H, Caforio ALP, Crea F, Goudevenos JA, Halvorsen S, Hindricks G, Kastrati A, Lenzen MJ, Prescott E, Roffi M, Valgimigli M, Varenhorst C, Vranckx P, Widimsky P, Group ESCSD (2018) 2017 ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation: the task force for the management of acute myocardial infarction in patients presenting with ST-segment elevation of the European Society of Cardiology (ESC). Eur Heart J 39:119–177. https://doi.org/10.1093/eurheartj/ehx393 CrossRefPubMed

59.

Inserte J, Cardona M, Poncelas-Nozal M, Hernando V, Vilardosa U, Aluja D, Parra VM, Sanchis D, Garcia-Dorado D (2016) Studies on the role of apoptosis after transient myocardial ischemia: genetic deletion of the executioner caspases-3 and -7 does not limit infarct size and ventricular remodeling. Basic Res Cardiol 111:18. https://doi.org/10.1007/s00395-016-0537-6 CrossRefPubMed

60.

Johnsen J, Pryds K, Salman R, Lofgren B, Kristiansen SB, Botker HE (2016) The remote ischemic preconditioning algorithm: effect of number of cycles, cycle duration and effector organ mass on efficacy of protection. Basic Res Cardiol 111:10. https://doi.org/10.1007/s00395-016-0529-6 CrossRefPubMed

61.

Jones SP, Tang XL, Guo Y, Steenbergen C, Lefer DJ, Kukreja RC, Kong M, Li Q, Bhushan S, Zhu X, Du J, Nong Y, Stowers HL, Kondo K, Hunt GN, Goodchild TT, Orr A, Chang CC, Ockaili R, Salloum FN, Bolli R (2015) The NHLBI-sponsored Consortium for preclinicAl assESsment of cARdioprotective therapies (CAESAR): a new paradigm for rigorous, accurate, and reproducible evaluation of putative infarct-sparing interventions in mice, rabbits, and pigs. Circ Res 116:572–586. https://doi.org/10.1161/CIRCRESAHA.116.305462 CrossRefPubMed

62.

Jung JE, Kim GS, Chen H, Maier CM, Narasimhan P, Song YS, Niizuma K, Katsu M, Okami N, Yoshioka H, Sakata H, Goeders CE, Chan PH (2010) Reperfusion and neurovascular dysfunction in stroke: from basic mechanisms to potential strategies for neuroprotection. Mol Neurobiol 41:172–179. https://doi.org/10.1007/s12035-010-8102-z CrossRefPubMedPubMedCentral

63.

Kleinbongard P, Peters J, Jakob H, Heusch G, Thielmann M (2018) Persistent survival benefit from remote ischemic pre-conditioning in patients undergoing coronary artery bypass surgery. J Am Coll Cardiol 71:252–254. https://doi.org/10.1016/j.jacc.2017.10.083 CrossRefPubMed

64.

Kloner RA, King KS, Harrington MG (2018) No-reflow phenomenon in the heart and brain. Am J Physiol Heart Circ Physiol 315:H550–H562. https://doi.org/10.1152/ajpheart.00183.2018 CrossRefPubMed

65.

Lapchak PA, Zhang JH (2018) Translational stroke research guideline projections: the 20/20 standards. Transl Stroke Res 9:9–12. https://doi.org/10.1007/s12975-017-0534-6 CrossRefPubMed

66.

Lapchak PA, Zhang JH, Noble-Haeusslein LJ (2013) RIGOR guidelines: escalating STAIR and STEPS for effective translational research. Transl Stroke Res 4:279–285. https://doi.org/10.1007/s12975-012-0209-2 CrossRefPubMed

67.

Lecour S, Bøtker HE, Condorelli G, Davidson SM, Garcia-Dorado D, Engel FB, Ferdinandy P, Heusch G, Madonna R, Ovize M, Ruiz-Meana M, Schulz R, Sluijter JP, Van Laake LW, Yellon DM, Hausenloy DJ (2014) ESC working group cellular biology of the heart: position paper: improving the preclinical assessment of novel cardioprotective therapies. Cardiovasc Res 104:399–411. https://doi.org/10.1093/cvr/cvu225 CrossRefPubMedPubMedCentral

68.

Li D, Shao Z, Vanden Hoek TL, Brorson JR (2007) Reperfusion accelerates acute neuronal death induced by simulated ischemia. Exp Neurol 206:280–287. https://doi.org/10.1016/j.expneurol.2007.05.017 CrossRefPubMedPubMedCentral

69.

Li W, Liu J, Chen JR, Zhu YM, Gao X, Ni Y, Lin B, Li H, Qiao SG, Wang C, Zhang HL, Ao GZ (2018) Neuroprotective effects of DTIO, a novel analog of Nec-1, in acute and chronic stages after ischemic stroke. Neuroscience 390:12–29. https://doi.org/10.1016/j.neuroscience.2018.07.044 CrossRefPubMed

70.

Li Y, He L, Huang X, IssaBhaloo S, Zhao H, Zhang S, Pu W, Tian X, Li Y, Liu Q, Yu W, Zhang L, Liu X, Liu K, Tang J, Zhang H, Cai D, Adams RH, Xu Q, Lui KO, Zhou B (2018) Genetic lineage tracing of non-myocyte population by dual recombinases. Circulation. https://doi.org/10.1161/circulationaha.118.034250 CrossRefPubMedPubMedCentral

71.

Liu RR, Murphy TH (2009) Reversible cyclosporin A-sensitive mitochondrial depolarization occurs within minutes of stroke onset in mouse somatosensory cortex in vivo: a two-photon imaging study. J Biol Chem 284:36109–36117. https://doi.org/10.1074/jbc.M109.055301 CrossRefPubMedPubMedCentral

72.

Madonna R, Cadeddu C, Deidda M, Mele D, Monte I, Novo G, Pagliaro P, Pepe A, Spallarossa P, Tocchetti CG, Zito C, Mercuro G (2015) Improving the preclinical models for the study of chemotherapy-induced cardiotoxicity: a position paper of the Italian Working Group on Drug Cardiotoxicity and Cardioprotection. Heart Fail Rev 20:621–631. https://doi.org/10.1007/s10741-015-9497-4 CrossRefPubMed

73.

Maulik A, Davidson SM, Piotrowska I, Walker M, Yellon DM (2018) Ischaemic preconditioning protects cardiomyocytes from anthracycline-induced toxicity via the PI3 K pathway. Drugs Ther, Cardiovasc. https://doi.org/10.1007/s10557-018-6793-y CrossRef

74.

McGowan JV, Chung R, Maulik A, Piotrowska I, Walker JM, Yellon DM (2017) Anthracycline chemotherapy and cardiotoxicity. Cardiovasc Drugs Ther 31:63–75. https://doi.org/10.1007/s10557-016-6711-0 CrossRefPubMedPubMedCentral

75.

Meybohm P, Bein B, Brosteanu O, Cremer J, Gruenewald M, Stoppe C, Coburn M, Schaelte G, Boning A, Niemann B, Roesner J, Kletzin F, Strouhal U, Reyher C, Laufenberg-Feldmann R, Ferner M, Brandes IF, Bauer M, Stehr SN, Kortgen A, Wittmann M, Baumgarten G, Meyer-Treschan T, Kienbaum P, Heringlake M, Schon J, Sander M, Treskatsch S, Smul T, Wolwender E, Schilling T, Fuernau G, Hasenclever D, Zacharowski K, Collaborators RIS (2015) A multicenter trial of remote ischemic preconditioning for heart surgery. N Engl J Med 373:1397–1407. https://doi.org/10.1056/NEJMoa1413579 CrossRefPubMed

76.

Moustafa RR, Baron JC (2008) Pathophysiology of ischaemic stroke: insights from imaging, and implications for therapy and drug discovery. Br J Pharmacol 153(Suppl 1):S44–S54. https://doi.org/10.1038/sj.bjp.0707530 CrossRefPubMed

77.

Murry CE, Reinecke H, Pabon LM (2006) Regeneration gaps: observations on stem cells and cardiac repair. J Am Coll Cardiol 47:1777–1785. https://doi.org/10.1016/j.jacc.2006.02.002 CrossRefPubMed

78.

Neuhaus AA, Couch Y, Hadley G, Buchan AM (2017) Neuroprotection in stroke: the importance of collaboration and reproducibility. Brain 140:2079–2092. https://doi.org/10.1093/brain/awx126 CrossRefPubMed

79.

Nighoghossian N, Berthezene Y, Mechtouff L, Derex L, Cho TH, Ritzenthaler T, Rheims S, Chauveau F, Bejot Y, Jacquin A, Giroud M, Ricolfi F, Philippeau F, Lamy C, Turc G, Bodiguel E, Domigo V, Guiraud V, Mas JL, Oppenheim C, Amarenco P, Cakmak S, Sevin-Allouet M, Guillon B, Desal H, Hosseini H, Sibon I, Mahagne MH, Ong E, Mewton N, Ovize M (2015) Cyclosporine in acute ischemic stroke. Neurology 84:2216–2223. https://doi.org/10.1212/WNL.0000000000001639 CrossRefPubMed

80.

O’Collins VE, Donnan GA, Macleod MR, Howells DW (2013) Hypertension and experimental stroke therapies. J Cereb Blood Flow Metab 33:1141–1147. https://doi.org/10.1038/jcbfm.2013.88 CrossRefPubMedPubMedCentral

81.

O’Collins VE, Macleod MR, Cox SF, Van Raay L, Aleksoska E, Donnan GA, Howells DW (2011) Preclinical drug evaluation for combination therapy in acute stroke using systematic review, meta-analysis, and subsequent experimental testing. J Cereb Blood Flow Metab 31:962–975. https://doi.org/10.1038/jcbfm.2010.184 CrossRefPubMed

82.

Pedersen F, Butrymovich V, Kelbaek H, Wachtell K, Helqvist S, Kastrup J, Holmvang L, Clemmensen P, Engstrom T, Grande P, Saunamaki K, Jorgensen E (2014) Short- and long-term cause of death in patients treated with primary PCI for STEMI. J Am Coll Cardiol 64:2101–2108. https://doi.org/10.1016/j.jacc.2014.08.037 CrossRefPubMed

83.

Pundik S, Xu K, Sundararajan S (2012) Reperfusion brain injury: focus on cellular bioenergetics. Neurology 79:S44–S51. https://doi.org/10.1212/WNL.0b013e3182695a14 CrossRefPubMed

84.

Rossello X, Yellon DM (2016) Cardioprotection: the disconnect between bench and bedside. Circulation 134:574–575. https://doi.org/10.1161/CIRCULATIONAHA.116.022829 CrossRefPubMed

85.

Rossello X, Yellon DM (2017) The RISK pathway and beyond. Basic Res Cardiol 113:2. https://doi.org/10.1007/s00395-017-0662-x CrossRefPubMedPubMedCentral

86.

Sandhu H, Maddock H (2014) Molecular basis of cancer-therapy-induced cardiotoxicity: introducing microRNA biomarkers for early assessment of subclinical myocardial injury. Clin Sci (Lond.) 126:377–400. https://doi.org/10.1042/CS20120620 CrossRef

87.

Saver JL (2006) Time is brain–quantified. Stroke 37:263–266. https://doi.org/10.1161/01.STR.0000196957.55928.ab CrossRefPubMed

88.

Savitz SI, Baron JC, Yenari MA, Sanossian N, Fisher M (2017) Reconsidering neuroprotection in the reperfusion Era. Stroke 48:3413–3419. https://doi.org/10.1161/STROKEAHA.117.017283 CrossRefPubMed

89.

Schinzel AC, Takeuchi O, Huang Z, Fisher JK, Zhou Z, Rubens J, Hetz C, Danial NN, Moskowitz MA, Korsmeyer SJ (2005) Cyclophilin D is a component of mitochondrial permeability transition and mediates neuronal cell death after focal cerebral ischemia. Proc Natl Acad Sci USA 102:12005–12010. https://doi.org/10.1073/pnas.0505294102 CrossRefPubMedPubMedCentral

90.

Schmidt M, Jacobsen JB, Lash TL, Botker HE, Sorensen HT (2012) 25 year trends in first time hospitalisation for acute myocardial infarction, subsequent short and long term mortality, and the prognostic impact of sex and comorbidity: a Danish nationwide cohort study. BMJ 344:e356. https://doi.org/10.1136/bmj.e356 CrossRefPubMedPubMedCentral

91.

Sloth AD, Schmidt MR, Munk K, Kharbanda RK, Redington AN, Schmidt M, Pedersen L, Sorensen HT, Botker HE (2014) Improved long-term clinical outcomes in patients with ST-elevation myocardial infarction undergoing remote ischaemic conditioning as an adjunct to primary percutaneous coronary intervention. Eur Heart J 35:168–175. https://doi.org/10.1093/eurheartj/eht369 CrossRefPubMed

92.

Sluijter JPG, Davidson SM, Boulanger CM, Buzas EI, de Kleijn DPV, Engel FB, Giricz Z, Hausenloy DJ, Kishore R, Lecour S, Leor J, Madonna R, Perrino C, Prunier F, Sahoo S, Schiffelers RM, Schulz R, Van Laake LW, Ytrehus K, Ferdinandy P (2018) Extracellular vesicles in diagnostics and therapy of the ischaemic heart: position Paper from the Working Group on cellular biology of the heart of the European Society of Cardiology. Cardiovasc Res 114:19–34. https://doi.org/10.1093/cvr/cvx211 CrossRefPubMed

93.

Smith CC, Davidson SM, Lim SY, Simpkin JC, Hothersall JS, Yellon DM (2007) Necrostatin: a potentially novel cardioprotective agent? Cardiovasc Drugs Ther 21:227–233. https://doi.org/10.1007/s10557-007-6035-1 CrossRefPubMed

94.

Stone GW, Selker HP, Thiele H, Patel MR, Udelson JE, Ohman EM, Maehara A, Eitel I, Granger CB, Jenkins PL, Nichols M, Ben-Yehuda O (2016) Relationship between infarct size and outcomes following primary PCI: patient-level analysis from 10 randomized trials. J Am Coll Cardiol 67:1674–1683. https://doi.org/10.1016/j.jacc.2016.01.069 CrossRefPubMed

95.

Szummer K, Wallentin L, Lindhagen L, Alfredsson J, Erlinge D, Held C, James S, Kellerth T, Lindahl B, Ravn-Fischer A, Rydberg E, Yndigegn T, Jernberg T (2017) Improved outcomes in patients with ST-elevation myocardial infarction during the last 20 years are related to implementation of evidence-based treatments: experiences from the SWEDEHEART registry 1995–2014. Eur Heart J 38:3056–3065. https://doi.org/10.1093/eurheartj/ehx515 CrossRefPubMedPubMedCentral

96.

Thielmann M, Kottenberg E, Kleinbongard P, Wendt D, Gedik N, Pasa S, Price V, Tsagakis K, Neuhauser M, Peters J, Jakob H, Heusch G (2013) Cardioprotective and prognostic effects of remote ischaemic preconditioning in patients undergoing coronary artery bypass surgery: a single-centre randomised, double-blind, controlled trial. Lancet 382:597–604. https://doi.org/10.1016/S0140-6736(13)61450-6 CrossRefPubMed

97.

Vermeulen Z, Segers VF, De Keulenaer GW (2016) ErbB2 signaling at the crossing between heart failure and cancer. Basic Res Cardiol 111:60. https://doi.org/10.1007/s00395-016-0576-z CrossRefPubMedPubMedCentral

98.

Vicencio JM, Yellon DM, Sivaraman V, Das D, Boi-Doku C, Arjun S, Zheng Y, Riquelme JA, Kearney J, Sharma V, Multhoff G, Hall AR, Davidson SM (2015) Plasma exosomes protect the myocardium from ischemia-reperfusion injury. J Am Coll Cardiol 65:1525–1536. https://doi.org/10.1016/j.jacc.2015.02.026 CrossRefPubMed

99.

Wang JC, Normand SL, Mauri L, Kuntz RE (2004) Coronary artery spatial distribution of acute myocardial infarction occlusions. Circulation 110:278–284. https://doi.org/10.1161/01.CIR.0000135468.67850.F4 CrossRefPubMed

100.

Xu X, Chua KW, Chua CC, Liu CF, Hamdy RC, Chua BH (2010) Synergistic protective effects of humanin and necrostatin-1 on hypoxia and ischemia/reperfusion injury. Brain Res 1355:189–194. https://doi.org/10.1016/j.brainres.2010.07.080 CrossRefPubMedPubMedCentral

101.

Zelniker TA, Braunwald E (2018) Cardiac and renal effects of sodium-glucose Co-transporter 2 inhibitors in diabetes: JACC state-of-the-art review. J Am Coll Cardiol 72:1845–1855. https://doi.org/10.1016/j.jacc.2018.06.040 CrossRefPubMed

102.

Zhang L, Zhang RL, Jiang Q, Ding G, Chopp M, Zhang ZG (2015) Focal embolic cerebral ischemia in the rat. Nat Protoc 10:539–547. https://doi.org/10.1038/nprot.2015.036 CrossRefPubMedPubMedCentral

Title: The 10th Biennial Hatter Cardiovascular Institute workshop: cellular protection—evaluating new directions in the setting of myocardial infarction, ischaemic stroke, and cardio-oncology
Authors: Sean M. Davidson
Sapna Arjun
Maryna V. Basalay
Robert M. Bell
Daniel I. Bromage
Hans Erik Bøtker
Richard D. Carr
John Cunningham
Arjun K. Ghosh
Gerd Heusch
Borja Ibanez
Petra Kleinbongard
Sandrine Lecour
Helen Maddock
Michel Ovize
Malcolm Walker
Marlene Wiart
Derek M. Yellon
Publication date: 01-11-2018
Publisher: Springer Berlin Heidelberg
Published in: Basic Research in Cardiology / Issue 6/2018
Print ISSN: 0300-8428
Electronic ISSN: 1435-1803
DOI: https://doi.org/10.1007/s00395-018-0704-z

ACC 2024 Congress Coverage

Heart Failure Video

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

The 10th Biennial Hatter Cardiovascular Institute workshop: cellular protection—evaluating new directions in the setting of myocardial infarction, ischaemic stroke, and cardio-oncology

Abstract

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 6/2018

Raf kinase inhibitor protein mediates myocardial fibrosis under conditions of enhanced myocardial oxidative stress

The role of Wnt signaling in the healing myocardium: a focus on cell specificity

Cardiac mesenchymal cells from diabetic mice are ineffective for cell therapy-mediated myocardial repair

Purinergic receptor Y2 (P2Y2)- dependent VCAM-1 expression promotes immune cell infiltration in metabolic syndrome

Uncoupling protein 3 deficiency impairs myocardial fatty acid oxidation and contractile recovery following ischemia/reperfusion

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page